Spinal Muscular Atrophy Sma clinical trials

Explore recruiting spinal muscular atrophy sma clinical trials.

Recruiting spinal muscular atrophy sma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Spinal Muscular Atrophy Sma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

Poland, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Open-label Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants with Spinal Muscular Atrophy

Norway, Italy, Belgium, Germany, Poland, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients with Spinal Muscular Atrophy After Gene Therapy

Germany, Poland

Therapeutic use (Phase IV) EU CTIS Study details

An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Risdiplam (RO7034067) in Adult and Pediatric patients with Spinal Muscular Atrophy

Netherlands, Italy, France, Poland, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Longitudinal study of clinical outcome measures in adult patients with Spinal Muscular Atrophy (SMA) treated with Risdiplam.

Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab (ONYX)

Poland, Belgium, France, Italy, Netherlands, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Spinal Muscular Atrophy Sma trials by city

Spinal Muscular Atrophy Sma in Toronto Spinal Muscular Atrophy Sma in Vancouver Spinal Muscular Atrophy Sma in Montreal Spinal Muscular Atrophy Sma in Calgary Spinal Muscular Atrophy Sma in Edmonton Spinal Muscular Atrophy Sma in Ottawa Spinal Muscular Atrophy Sma in Winnipeg Spinal Muscular Atrophy Sma in Quebec City Spinal Muscular Atrophy Sma in Hamilton Spinal Muscular Atrophy Sma in Kitchener Spinal Muscular Atrophy Sma in London Spinal Muscular Atrophy Sma in Halifax Spinal Muscular Atrophy Sma in New York Spinal Muscular Atrophy Sma in Los Angeles Spinal Muscular Atrophy Sma in Chicago Spinal Muscular Atrophy Sma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease